Subjects phenotyped for CYP3A activity with MDZ and 4β-OHC tests
| Characteristic | Control MDZ/4β-OHC (n = 20) | NAFLD MDZ (n = 10) | NAFLD 4β-OHC (n = 30) |
|---|---|---|---|
| Age, yr (range) | 43 (28–58) | 51 (27–63) | 49 (27–69) |
| Sex | |||
| Men | 7 | 5 | 19 |
| Women | 13 | 5 | 11 |
| Body mass index (range) | 24 (19–30) | 35 (28–45) | 33 (23–45) |
| HOMA IR (range) | — | 3.5 (1.7–6.5) | 3.1 (1–9.6) |
| NAFLD stagea | |||
| SS | — | 1 | 7 |
| NASH | — | 9 | 23 |
| Fibrosisb | |||
| No fibrosis | — | 1 | 6 |
| Fibrosis | — | 9 | 24 |
| Allele carrier statusc | |||
| CYP3A4*22 | 17/0/0 | 9/1/0 | 24/6/0 |
| CYP3A5*3 | 0/1/16 | 0/2/8 | 0/7/23 |
| PPARα (rs4253728) | 12/5/0 | 6/4/0 | 16/12/2 |
| POR*28 | 10/6/1 | 5/5/0 | 13/14/3 |
| PNPLA3 (rs738409) | — | 2/7/1 | 9/14/7 |
↵a NASH was defined as an NAS [steatosis (0–3), lobular inflammation (0–3), and hepatocellular ballooning (0–2)] ≥3 plus a hepatocellular ballooning score ≥1. SS was defined as an NAS <3 or an NAS ≤3 with a ballooning score of 0.
↵b Degree of fibrosis was categorized by histologic fibrosis score (0–4; no fibrosis = 0 and fibrosis = ≥1).
↵c Number of noncarriers/heterozygous carriers/homozygous carriers. For the control group, genotype was available for 17 of 20 subjects.